MarketCap
Facebook
X
TelegramGeschäftsbericht 2025
hinzugefügt 31.03.2026
BioAtla Kurzfristige Verbindlichkeiten 2011-2026 | BCAB
Kurzfristige Verbindlichkeiten Jährlich BioAtla
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 21.9 M | 14.5 M | 28.3 M | 23.1 M | 19.8 M | - | - | - | - | - | - | - | - | - | - |
Alle Zahlen in USD-Währung
Indikatorenreichweite aus Jahresberichten
| Höchstwert | Mindestwert | Durchschnitt |
|---|---|---|
| 28.3 M | 14.5 M | 21.6 M |
Kurzfristige Verbindlichkeiten anderer Aktien in der Pharmaeinzelhändler
| Name | Kurzfristige Verbindlichkeiten | Preis | % 24h | Marktkapitalisierung | Land | |
|---|---|---|---|---|---|---|
 |
Coherus BioSciences
CHRS
|
140 M | $ 1.57 | -3.68 % | $ 184 M |  USA |
 |
Happiness Biotech Group Limited
HAPP
|
6.4 M | - | 1.35 % | $ 17.8 M |  China |
 |
Amphastar Pharmaceuticals
AMPH
|
158 M | $ 16.87 | -2.49 % | $ 789 M | USA |
 |
AgeX Therapeutics
AGE
|
3.56 M | - | -10.17 % | $ 12.2 K | USA |
 |
I-Mab
IMAB
|
576 M | - | - | $ 866 M | China |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
1.62 B | - | - | $ 40.3 B | USA |
 |
EyeGate Pharmaceuticals, Inc.
EYEG
|
1.77 M | - | -1.52 % | $ 24.7 M | USA |
 |
Arcturus Therapeutics Holdings
ARCT
|
36.4 M | $ 7.47 | -4.6 % | $ 205 M |  Israel |
 |
Athira Pharma
ATHA
|
47.5 M | - | - | $ 269 M | USA |
 |
Eton Pharmaceuticals
ETON
|
38.5 M | $ 30.26 | 1.0 % | $ 814 M | USA |
 |
Galera Therapeutics
GRTX
|
645 K | - | -32.59 % | $ 7.61 M | USA |
 |
Exelixis
EXEL
|
406 M | $ 50.13 | -1.9 % | $ 13.6 B | USA |
 |
Fortress Biotech
FBIO
|
49.7 M | $ 2.41 | 4.78 % | $ 67.2 M | USA |
|
Forte Biosciences
FBRX
|
20.8 M | $ 23.11 | -3.55 % | $ 299 M | USA |
 |
AbCellera Biologics
ABCL
|
64.3 M | $ 4.09 | -7.05 % | $ 1.22 B |  Canada |
 |
Autolus Therapeutics plc
AUTL
|
73.4 M | $ 1.63 | 2.52 % | $ 434 M |  Britain |
 |
Институт стволовых клеток человека
ISKJ
|
556 M | - | - | - |  Russia |
 |
Checkmate Pharmaceuticals
CMPI
|
9.38 M | - | - | $ 231 M | USA |
 |
Galectin Therapeutics
GALT
|
8.03 M | $ 2.17 | -7.66 % | $ 139 M | USA |
 |
Berkeley Lights
BLI
|
45.5 M | - | -7.31 % | $ 87 M | USA |
 |
Generation Bio Co.
GBIO
|
35.1 M | - | - | $ 344 M | USA |
 |
Akero Therapeutics
AKRO
|
39.8 M | - | - | $ 3.67 B | USA |
 |
Ayala Pharmaceuticals
AYLA
|
7.54 M | - | - | $ 7.46 M | Israel |
 |
Gilead Sciences
GILD
|
11.8 B | $ 129.58 | -1.88 % | $ 161 B | USA |
 |
Advaxis
ADXS
|
25 M | - | -9.65 % | $ 45.9 M | USA |
 |
Can-Fite BioPharma Ltd.
CANF
|
2.73 M | $ 3.36 | -3.72 % | $ 5.53 M | Israel |
 |
Aeglea BioTherapeutics
AGLE
|
58.7 M | - | - | $ 1.01 B | USA |
 |
Applied Genetic Technologies Corporation
AGTC
|
25.2 M | - | - | $ 26.5 M | USA |
 |
AIkido Pharma
AIKI
|
1.61 M | - | 1.93 % | $ 17.4 M | USA |
|
Enlivex Therapeutics Ltd.
ENLV
|
9.02 M | $ 0.72 | -1.58 % | $ 32.9 M | Israel |
 |
Esperion Therapeutics
ESPR
|
301 M | $ 3.12 | - | $ 649 M | USA |
 |
Aptose Biosciences
APTO
|
9.31 M | - | -45.71 % | $ 1.2 M | Canada |
 |
Aptinyx
APTX
|
6.29 M | - | -39.0 % | $ 4.57 M | USA |
 |
Akouos
AKUS
|
16.8 M | - | 0.23 % | $ 488 M | USA |
 |
Albireo Pharma
ALBO
|
45.3 M | - | -0.23 % | $ 916 M | USA |
 |
AlloVir
ALVR
|
9.71 M | - | 4.14 % | $ 49.1 M | USA |
 |
Allakos
ALLK
|
17.8 M | - | - | $ 28.6 M | USA |